Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab ± Tiragolumab Consolidation in Limited-Stage SCLC After Chemoradiotherapy
CTR20192655Phase 2Terminated
- Sponsor
- Roche
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, tiragolumab in small cell lung cancer (SCLC), sponsored by Roche. Started Jan 2020; status: terminated.
02
Drugs
atezolizumabtiragolumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20192655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192655.